206 results
P
Hepatocellular carcinomas (HCCs), non-HCC malignancies
I/C
Contrast-enhanced ultrasound (CEUS) Liver Imaging Reporting and Data System category M (LR-M), CEUS LR-M category, Non-HCC malignancies
O
Proportion of CEUS LR-M in HCC and non-HCC malignancies, Frequency of individual CEUS LR-M imaging features
P
patients with liver lesions
I/C
LI-RADS algorithm, original studies reporting probability of LR-M for HCC and non-HCC malignancy on MRI
O
pooled percentages of HCC and non-HCC malignancy for LR-M, sources of heterogeneity between reported results
P
patients with cancers
I/C
F-NLR scoring system, high F-NLR score vs. low F-NLR score
O
overall survival (OS) and disease-free survival (DFS)/progression-free survival (PFS)
P
bladder cancer (BC) patients
I/C
18 F-FDG PET/CT, clinical response and nonresponse
O
tumor response to neoadjuvant chemotherapy
P
thyroid cancer (TCa) patients
I/C
F-18 fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT), ultrasonography (US)
O
detection of cervical lymph node (LN) metastasis
P
patients with vertebral compression fractures
I/C
F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT), differentiation of benign and malignant vertebral compression fractures
O
diagnostic performance, sensitivity, specificity, positive likelihood ratio, negative likelihood ratio
P
rodents
I/C
unmodified MSC(M), controls
O
mortality rate
P
gynecological cancer
I/C
18 F-FDG PET, management of patients with recurrent gynecological cancers
O
changes in management
P
HIV-infected adults with tuberculosis
I/C
Mycobacterium tuberculosis bloodstream infection (BSI), Patients with HIV-associated tuberculosis but without M. tuberculosis BSI
O
Mortality within 30 days
P
Asian people living with HIV
I/C
switching to bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF), staying on baseline regimens
O
maintained 100% virological suppression at week 48 with no treatment-emergent drug resistance and safety profiles comparable to those seen in people who stayed on baseline regimens